Market closed

Geron/$GERN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Geron

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Ticker

$GERN
Trading on

Industry

Biotechnology

Employees

141

Geron Metrics

BasicAdvanced
$2.4B
Market cap
-
P/E ratio
-$0.32
EPS
0.51
Beta
-
Dividend rate
$2.4B
0.51
$5.34
$1.64
8.4M
2.886
2.681
5.041
29.856
-17.16%
-30.30%
-69.03%
84.675
8.19
8.19
-11.53
9,199.68%
-5.33%
318.22%
-1.25%

What the Analysts think about Geron

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Geron stock.

Geron Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Geron Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GERN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Geron stock?

Geron (GERN) has a market cap of $2.4B as of November 14, 2024.

What is the P/E ratio for Geron stock?

The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of November 14, 2024.

Does Geron stock pay dividends?

No, Geron (GERN) stock does not pay dividends to its shareholders as of November 14, 2024.

When is the next Geron dividend payment date?

Geron (GERN) stock does not pay dividends to its shareholders.

What is the beta indicator for Geron?

Geron (GERN) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.